Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore
LONDON, Nov. 10, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces its first dedicated Medical Education Centre to support customers across the Asia Pacific region. Smith+Nephew's Medical Education Centre in Singapore Strategically located in Singapore, the centre will support the safe and effective...
One BioMed launches the cartridge-based Xceler8(TM) Nucleic Acid Extraction Platform, the next generation in workflow simplification
SINGAPORE, Nov. 10, 2021 /PRNewswire/ -- One BioMed, a company focused on advancing human health through innovation, announced today the launch of their Xceler8™ Platform for high-yield extraction and purification of nucleic acids from biological samples. Pre-filled with all the necessary reagents, X8™ Cartridge Kits, powered by the OneTouch Instrument and its touchscreen tablet, automate all nucleic acid extraction steps,...
Prenetics Announces Strong First Half 2021 Financial Results as Company Progresses Towards a U.S. Nasdaq Listing in Partnership with Artisan Acquisition Corp.
Revenue reached US$136.5 million, up 1,039% year-over-year Adjusted EBITDA was US$31.5 million, increased by US$34.6 million year-over-year Prenetics has publicly filed a registration statement on Form F-4 with the SEC in connection with its proposed business combination with Artisan Acquisition Corp (Nasdaq: ARTAU, "Artisan"). The transaction is expected to close in the first quarter of 2022 Prenetics reaffirms...
Bon Natural Life Limited Announces Corporate Reorganization and Removal of VIE Structure
XI'AN, China, Nov. 9, 2021 /PRNewswire/-- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced it has removed its variable interest entity ("VIE") structure and has become the sole shareholder of its operating entities in China. Effective November 1, 2021, the...
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery,...
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided...
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative
MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health...
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System....
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administration (FDA). The IND was submitted by the University of Rochester Medical Center, New York...
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting
SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the acceptance of an abstract at the upcoming 2021 American Society of Hematology (ASH) Annual...
